Study on immunogenicity elicited by a recombinant vaccine of rBCG-Rv3133c to fight against dormancy Mycobacterium tuberculosis / 生物医学工程学杂志
Journal of Biomedical Engineering
;
(6): 817-821, 2013.
Article
in Chinese
| WPRIM
| ID: wpr-352159
ABSTRACT
To obtain a vaccine to defend from dormancy Mycobacterium tuberculosis, we constructed the recombinant Bacilli Calmette-Guérin (BCG) vaccine with Rv3133c encoding dormancy-correlated transcriptional regulatory protein DosR in Mycobacterium tuberculosis as a target gene, and evaluated its immunogenicity in BALB/c mice. In this study, we constructed the recombinant plasmids of rpMV361-Rv3133c using gene colon technology. We then transformed BCG strains with above-mentioned plasmids to obtain recombinant vaccine of rBCG-Rv3133c. We used the rBCG strains successfully constructed to vaccinate in BALB/c mice. 30d and 180d after immunization, the specific antibody titers were determined to investigate humoral responses induced by recombinant vaccine. We detected changes of splenocyte subsets of CD4+T, CD8+ T cells and cytokine of IFN-gamma secreted by splenocytes for evaluation of cellular immune responses. The results showed that the rBCG-Rv3133c was able to induce higher levels of antibody titer, stronger proliferative responses and higher IFN-gamma production comparing with BCG vaccine. The results also suggested that this recombinant vaccine was a more efficacious tuberculosis vaccine for further study.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Protein Kinases
/
Bacterial Proteins
/
Tuberculosis
/
Blood
/
Recombinant Proteins
/
BCG Vaccine
/
Vaccines, Synthetic
/
T-Lymphocyte Subsets
/
Interferon-gamma
/
Vaccination
Limits:
Animals
Language:
Chinese
Journal:
Journal of Biomedical Engineering
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS